Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo Adverse events up to week 12 · Participants with active Crohn's disease Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane | RR 0.91 [0.75, 1.09] | 1 study · 131 participants | Moderate |
One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo Withdrawal due to adverse events up to week 12 · Participants with active Crohn's disease Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane | RR 0.46 [0.04, 4.98] | 1 study · 131 participants | Low |
One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo Serious adverse events up to week 12 · Participants with active Crohn's disease Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane | RR 0.93 [0.34, 2.49] | 1 study · 131 participants | Low |
Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo Failure to induce remission at 6 weeks · Participants with active Crohn's disease Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane | RR 0.85 [0.78, 0.93] | 2 studies · 1034 participants | High |
Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo Failure to induce remission at 8 weeks · Participants with active Crohn's disease Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane | RR 0.85 [0.76, 0.95] | 3 studies · 1543 participants | Moderate |
Interventions vs placebo or no prophylaxis Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.47 [0.39, 0.57] | 30 studies · 3207 participants | Moderate |
H2 receptor antagonists vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 2 studies · 230 participants | Low |
H2 receptor antagonists vs placebo or no prophylaxis Number of participants requiring blood transfusions · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.58 [0.36, 0.95] | 7 studies · 655 participants | Moderate |
H2 receptor antagonists vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Proton pump inhibitors vs placebo or no prophylaxis Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.63 [0.18, 2.22] | 3 studies · 237 participants | Low |
Proton pump inhibitors vs placebo or no prophylaxis Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.24 [0.77, 1.98] | 2 studies · 227 participants | Low |
Proton pump inhibitors vs placebo or no prophylaxis All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.09 [0.6, 1.99] | 3 studies · 258 participants | Low |
Proton pump inhibitors vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 2 studies · 227 participants | Low |
Proton pump inhibitors vs placebo or no prophylaxis Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Proton pump inhibitors vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.49 [0.25, 0.99] | 8 studies · 774 participants | Low |
Interventions vs placebo or no prophylaxis Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.15 [0.9, 1.48] | 9 studies · 1331 participants | Low |
Antacids vs placebo or no prophylaxis Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.01 [0.53, 1.96] | 2 studies · 300 participants | Low |
Antacids vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs placebo or no prophylaxis Number of participants requiring blood transfusions · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.94 [0.3, 2.96] | 2 studies · 226 participants | Low |
Antacids vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Sucralfate vs placebo or no prophylaxis Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.53 [0.32, 0.88] | 7 studies · 598 participants | Moderate |
Sucralfate vs placebo or no prophylaxis Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.33 [0.86, 2.04] | 4 studies · 450 participants | Low |
Sucralfate vs placebo or no prophylaxis All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.97 [0.66, 1.43] | 5 studies · 500 participants | Low |
Sucralfate vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 2 studies · 224 participants | Low |
Sucralfate vs placebo or no prophylaxis Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.6 [0.15, 2.44] | 1 study · 200 participants | Low |
Interventions vs placebo or no prophylaxis All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.1 [0.9, 1.34] | 19 studies · 2159 participants | Low |
Sucralfate vs placebo or no prophylaxis Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs proton pump inhibitors Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 2.9 [1.83, 4.58] | 13 studies · 1636 participants | Low |
H2 receptor antagonists vs proton pump inhibitors Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.02 [0.77, 1.35] | 10 studies · 1256 participants | Low |
H2 receptor antagonists vs proton pump inhibitors All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.96 [0.78, 1.19] | 12 studies · 1564 participants | Low |
H2 receptor antagonists vs proton pump inhibitors Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 5 studies · 482 participants | Low |
H2 receptor antagonists vs proton pump inhibitors Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.98 [0.75, 5.21] | 3 studies · 575 participants | Moderate |
H2 receptor antagonists vs proton pump inhibitors Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs antacids Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.96 [0.67, 1.36] | 16 studies · 1700 participants | Low |
H2 receptor antagonists vs antacids Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.05 [0.81, 1.36] | 4 studies · 581 participants | Low |
H2 receptor antagonists vs antacids All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.01 [0.66, 1.55] | 11 studies · 1321 participants | Very low |
Interventions vs placebo or no prophylaxis Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 2 studies · 447 participants | Low |
H2 receptor antagonists vs antacids Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs antacids Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 2.49 [1.35, 4.62] | 6 studies · 744 participants | Moderate |
H2 receptor antagonists vs antacids Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
H2 receptor antagonists vs sucralfate Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.1 [0.87, 1.41] | 24 studies · 3316 participants | Low |
H2 receptor antagonists vs sucralfate Nosocomial pneumonia · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.22 [1.07, 1.4] | 17 studies · 3041 participants | Moderate |
H2 receptor antagonists vs sucralfate All‐cause mortality in ICU · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.09 [0.95, 1.24] | 21 studies · 3178 participants | Low |
H2 receptor antagonists vs sucralfate Duration of ICU stay · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | 6 studies · 1791 participants | Very low |
H2 receptor antagonists vs sucralfate Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1.25 [0.7, 2.23] | 9 studies · 1095 participants | Low |
H2 receptor antagonists vs sucralfate Serious adverse events · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | no estimate extracted | NR | No studies |
Antacids vs sucralfate Clinically important upper GI bleeding · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 1 [0.72, 1.39] | 16 studies · 1772 participants | Low |
Interventions vs placebo or no prophylaxis Number of participants requiring blood transfusion · people admitted to intensive care units Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units (2018) · Cochrane | RR 0.63 [0.41, 0.97] | 9 studies · 981 participants | Moderate |